top
Search terms
Results 1 - 9 of 9 - ordered by :
Ehjcvp

Abstract Aims Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 6070% of patients admitted with acute coronary syndromes in clinical practice. The current guidelines of the ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Articles, Uwe Zeymer, Petr Widimsky, Nicolas Danchin, Maddalena Lettino, Alfredo Bardaji, Jose A. Barrabes, Angel Cequier, Marc J. ...

Date : 01/10/2016 Item size : 357401 bytes
Ehjcvp

Using a Cox proportional hazard model adjusting for baseline characteristics, use of apixaban [hazard ratio (HR) 0.70, 95% confidence interval (CI) 0.610.80, P0.001] and dabigatran (HR 0.74, 95% CI ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Sigrun Halvorsen, Waleed Ghanima, Ingunn Fride Tvete, Cecilie Hoxmark, PÃ¥l Falck, Oddvar Solli, Christian Jonasson

Date : 27/09/2016
Ehjcvp

Introduction Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) have been used in clinical practice for more than a century and are among the most widely used drugs worldwide for the ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Morten Schmidt, Morten Lamberts, Anne-Marie Schjerning Olsen, Emil Fosbøll, Alexander Niessner, Juan Tamargo, Giuseppe Rosano, ...

Date : 01/04/2016 Item size : 461588 bytes
Ehjcvp

Abstract Aims Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 6070% of patients admitted with acute coronary syndromes in clinical practice. The current guidelines of the ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Uwe Zeymer, Petr Widimsky, Nicolas Danchin, Maddalena Lettino, Alfredo Bardaji, Jose A. Barrabes, Angel Cequier, Marc J. ...

Date : 03/03/2016 Item size : 360655 bytes
Ehjcvp

While the absolute number of comorbidities such as renal disease, liver disease, chronic obstructive pulmonary disease, and vascular disease has increased, there was a relative decrease of ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Lorenz Koller, Alexander Niessner

Date : 01/07/2015
Ehjcvp

[...]the three pivotal clinical trials investigating the use of beta-blockers in HF (CIBIS II, COPERNICUS, and MERIT-HF) showed an approximate 34% relative reduction in mortality.13 ACE inhibitors ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Massimo Volpe, Pietro Francia

Date : 01/07/2015
Ehjcvp

Effects of reninangiotensinaldosterone system blockade on cardiovascular system The benefits of blocking the RAAS in heart failure (HF) and post-myocardial infarction (MI) were largely proved many ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Gema Ruiz-Hurtado, Luis Miguel Ruilope

Date : 01/04/2015
Ehjcvp

[...]of progress made in HFREF therapy, cumulative mortality benefit amounts to almost a three-fold decrease in death rate whether in severe or in mild-to-moderate HFREF. In chronic HEFREF, it is ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Faiez Zannad

Date : 01/01/2015 Item size : 180641 bytes
Ehjcvp

Thanks to these investigations, European and American scientific societies have developed guidelines that provide evidence-based recommendations for treating acute and chronic HF,1,2 including ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Francesco Pelliccia, Giuseppe M.C. Rosano

Date : 01/01/2015 Item size : 131344 bytes